**Pending questions in venous ulcers management. Report from a Symposium of the World Union of Wound Healing Societies International Congress**

Giorgio Guarnera,1 Paolo Zamboni,2 Ole Nelzen,2 Ferdinando Mannello,4 Anneke Andriessen5

1Department of Vascular Surgery, Aurelia Hospital, Rome, Italy; 2Vascular Diseases Center, University of Ferrara, Italy; 3Vascular Surgery Departments of Research and Development and Vascular Surgery, Skaraborg Hospital Skövde, Sweden; 4Section of Clinical Biochemistry and Molecular Genetics, Department of Biomolecular Sciences, University Carlo Bo, Urbino, Italy; 5Radboud UMC, Nijmegen & Andriessen Consultants, Malden, The Netherlands

**Abstract**

Venous ulcers represent the most frequent ulcers and have a high clinical and socioeconomic significance. Nevertheless, pending questions remain on epidemiology, genetic and biomolecular mechanisms, contraindications and risk factors of compression therapy, role of pharmacological therapy. Overall prevalence in the range of 1.2% and point prevalence of 0.08-0.6% can be reduced if risk factors are identified and treated early. In this context, analysis of factor XIII and hemocromatosis gene polymorphisms, with the C282Y and H63D variants, may be of great importance. Also MMP12 gene polymorphism and the imbalance between matrix metalloproteinases and their tissue inhibitors are able to impair wound healing via deleterious degradation process of extracellular matrix. From a therapeutic point of view, conflicting recommendations exist on relative contraindications, risks and adverse events of compression therapy. Some studies showed that the administration of pentoxiphylline, Micronized purified flavonoid fraction (MPFF) and sulodexide was effective in accelerating ulcer healing, but there is no data on the duration of treatment, recurrence rates and cost-effectiveness relationship.

**Introduction**

During World Union of Wound Healing Societies International Congress (25-29 of September 2016, Florence, Italy) a Scientific Session was held on venous ulcers with the aim of discussing controversies in this pathology management.

Venous ulcers are the most frequent leg ulcers. Clinical pathways for patients with venous leg ulcers should include accurate diagnosis and the use of appropriate diagnostic and therapeutic tools. Nevertheless there are many open issues in terms of epidemiology, pathophysiology and treatment.

Willingly, we did not deal with well-known topics such as superficial venous reflux abolition (ESCHAR study underlined the importance of surgery in preventing recurrences) or venous ulcers local therapy. On the contrary, we have chosen current topics with the objective of draw attention on controversial issues in venous ulcers.

The article presents ideas, experiences and suggestions offered by known Specialists in different medical branches, in order to answer provocative questions on pending issues in venous ulcers management. The aim of the paper is to identify gaps in the evidence and methodological deficiencies and assess future research needs for chronic venous ulcer care.

**What is the real prevalence of venous ulcers?**

There are very few epidemiological studies to generate data from and most of them are 10-30 years old. There are no newer estimates available. There have been several epidemiological studies performed reporting on leg ulcer point prevalence, but without properly defining the causes of the ulcers. We often talk about leg ulcers as being venous in a majority of cases when in fact the true point prevalence is largely unknown. Only very few have determined the etiology by means of objective assessment tools, such as color Doppler ultrasound (CDU) or plethysmography. In a Swedish study in Skaraborg detailed assessment showed that only half were of pure venous origin, at that time a point prevalence of 0.16%. There are several ways of looking at the various forms of prevalence, point, period and overall (Table 1). It is important to realize that they all mean different things. Point prevalence is different from period prevalence and overall or lifetime prevalence and they should not be mixed up. We are mostly talking about point prevalence expressing how many are having active ulcers at any one point of time or how many that will ever get a venous ulcer (overall prevalence). Another problem in assessing prevalence is that most studies have based their estimates on patients known to and taken care of within the health care system. In addition to that there are people taking care of their ulcers by themselves and that can only be assessed by performing random samples studies based on the entire population. The true prevalence is therefore higher than what is registered within the health care system.

Incidence is yet another measurement usually meaning how many new cases (first time) that will be expected during one year (Table 1). It seems that around one out of ten patients with venous ulcer has a first time ulcer with a duration of less than one year. The yearly incidence has been estimated to be in the range of 10-30/100,000 population in the western world. The figure of 1% having ever had a venous ulcer is probably a fairly correct estimate since it has been reproduced in several studies. Similar levels were found in the two most recent population studies on venous disease from the Bonn vein study in Germany and the Edinburgh vein study in Scotland. The point prevalence may vary a lot depending on how actively CDU has been used in ulcer diagnosis and to what extent surgical intervention have been used to eradicate superficial venous incompetence. It is important to realize that also patients that heal readily following compression treatment benefit from surgical intervention due to its superior effectiveness in preventing recurrent ulceration. Without early surgical inter-
vvention in these cases point prevalence is likely to stay high or even increase. There are no data showing that conservative management can reduce the point prevalence of venous ulcer and most experts are expecting an increasing number of patients with venous ulcer due to ageing populations.9

This results in a wide range for point prevalence estimates of active venous ulcer from 0.08% up to 0.6%.3 There are more available and stable data regarding overall or lifetime prevalence of venous ulceration that can be expected to be in the range of 1-2% and to lower that figure is more difficult and requires wide use of durable varicose vein treatments in our populations throughout many decades. Recurrence is lowered effectively by surgery as opposed to conservative compression alone.1 Varicose vein surgery and also never endovenous techniques to ablate saphenous vein incompetence have been shown effective in preventing recurrence and also (since this presentation was given) duplicate improve ulcer recurrence.15 Also in Skaraborg, Sweden, point prevalence was followed closely by using objective diagnostics and repeated epidemiological cross-sectional studies performed 2002 and 2014.11,12 These studies allowed us to monitor the effect of management and treatment changes to improve the outcomes. Per preliminary data the point prevalence has been reduced by some 70% from 1988, point prevalence 0.16 and down to 0.05% in 2014.11,12

Increased use of early surgical intervention based on proper diagnosis with CDU is likely to halt and reduce the feared increase of venous ulceration in the world.

### Is there a genetic predisposition to venous leg ulcers?

We concentrated our attention to three gene families, based on notions of pathophysiology which candidate the followings: i) iron trafficking genes. In chronic venous insufficiency the iron overload in the tissue is visible at naked eye. Activation of Fenton reaction with production of free radicals and, in turn, matrix metalloproteinases (MMPs) activation are pathways deeply investigated in venous leg ulceration;13-17 ii) factor XIII polymorphisms. Activated factor XIII (FXIIIa) is responsible for the cross-linking of fibrin monomers during the stabilization process of thrombus,18 and we basically know it as a key element of the hemostatic process. To the contrary, although less reported, FXIIIa plays a pivotal role in the stabilization of the provisional extra-cellular matrix (ECM) during any healing process. FXIIIa is also responsible in shutting the provisional matrix towards the definitive one. Because the polymorphisms of Factor XIII are numerous, frequent, and capable to change the molecular properties they were investigated by our group.18-20 iii) MMPs. It has been demonstrated, in course of severe venous stasis and/or venous leg ulcers an elevated gene expression for several families of MMPs and a reduced one for tissue inhibitor of MMPs (TIMPs). Such unrestricted MMPs proteolytic activity is commonly considered the final executioner of a pathogenetic chain leading to matrix disruption and ulcer development.18-19 This event together with the interstitial migration of macrophages have been proven to be fundamental component of the inflammatory cascade activated in the matrix in course of chronic venous disease (CVD).21,22 Now this appears at the beginning of the paragraph describing the genetics of venous leg ulcers (VLU). Although the number of factors involved in the etiology of chronic wounds is extremely high, a recognition of functional gene variants significantly involved in wound healing and venous ulcer establishment, may help our prognosis, diagnosis and treatment capabilities of chronic wounds. Over the years, we can read rigorous analyses of FXIII and mutated hemochromatosis protein [human factors engineering (HFE)] gene polymorphism and their prognostic implication in precocious ulcer onset and in healing time after superficial venous surgery.18,20,23 HFE gene polymorphisms, with the C282Y and H63D variants, are the most commonly recognized genetic defects in iron metabolism, and they have a vital role in predicting ulcer development. Since the iron hypothesis does not explain why leg iron deposits in CVD produce lesions only in some individuals, it was hypothesized that such individual differences could be genetically determined on the basis of HFE gene mutations, which are associated with an increased iron efflux from the macrophage.14,15,24-25 An example of the gene–environment interaction is reflected by an increased risk of 6- to 7-fold for VLU onset when there coexists an overlapping condition of CVD and C282Y carrier condition.26 Similarly, gene variant analysis of FXIII had given an important clinical conclusion in predicting clinical phenotypes to investigate the healing time and ulcer size in chronic wounds.27 Val34Leu polymorphism, strictly associated to the thrombin activation site, is the main functional polymorphism influencing FXIII activation with its approved role in increasing the catalytic efficiency of the molecule and the rate of fibrin clot stabilization with potent capacity to alter the structure of fibrin clot. Higher plasma FXIII activity, because of Val34Leu variant, may link more α2-antiplasmin to fibrin and thus causes the formation of more rigid and tougher fibrin gel that is chemically/mechanically more stable as well as resistant to fibrinolysis, mitigating the plasmin-dependent activation process of pro-MMPs by direct plasmin-antiplasmin inhibition. An earlier-activated FXIII molecule becomes more available to cross-link ECM components, stabilizing them against wasteful proteolysis.18-20,23

In a successive cohort of CVU subjects, we investigated if there was some relation between FXIII variants (Val34Leu, Pro564Leu, Tyr204Phe, His95Arg) and venous ulcer surface. After genotyping of cases and controls, the statistical analysis showed no differences in genotype frequencies for all polymorphisms studied, thus excluding any risk role in CVU establishment ascribable to these FXIII gene variants. The main finding of this study was the protective role of Leu34 and Leu564 polymorphisms in the whole group and primary CVU, whereas in the post thrombotic cases it did not show any protective role. The area of the ulcer was inversely related with the presence of the Leu34 and Leu564 allele in an independent fashion and without synergistic effects (hazard ratio, 4.14; 95% confidence interval, 2.1 to 8.2; Leu 34 P value=0.00005; Leu564: P value=0.00005). In this view these 2 variants of FXIIIa can be considered as modulators in lesion progression and extension.18 Also the role of MMP gene variants was suspected in clinical manifestation of CVD.22,21 Recently, we investigated single nucleotide polymor-

---

**Table 1. Terminology of ulcers epidemiology (World Health Organization)**13

<table>
<thead>
<tr>
<th>Type</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incidence</td>
<td>Number of new cases usually per year and in relation to the population</td>
</tr>
<tr>
<td>Point prevalence</td>
<td>Proportion of people with open ulcers at a certain short time frame (1-2 months)</td>
</tr>
<tr>
<td>Period prevalence</td>
<td>Proportion of people with open ulcers during a longer time frame (usually 1 year)</td>
</tr>
<tr>
<td>Overall prevalence</td>
<td>All people who have ever suffered from an ulcer (open + healed; lifetime prevalence)</td>
</tr>
</tbody>
</table>

[Veins and Lymphatics 2020; 9:9206] [page 67]
phism (SNPs) in the promoter region of the MMP12 gene (MMP12; -82AG) that might have a role in leg ulcer progression as well as in other complex diseases via ECM degradation. Concerning the role of our previous SNPs as prognostic markers in CVD, we propose MMP12 gene polymorphism (-82AG) as a putative prognostic marker in VLU progression.27 The immediate clinical application of gene variant analysis and evaluation implies that the high-risk minority of patients could be identified in advance. We think that a simple blood test could act as a genetic screening device. Based on the data shown above, prevention programs of VLU in primary varicose veins could be extraordinarily improved by using genetic markers in our initial patient assessment.

Biochemical and molecular markers in wound healing

The discovery of novel genomic, transcriptomic and proteomic biomarkers may significantly help the improvement of risk assessment, prevention strategies and medical decision making in the field of CVD.

A number of studies suggested that proteins regulating extracellular matrix turnover and remodeling are involved in Chronic venous insufficiency (CVI) evolution and progression;28 in this respect, ECM-degrading proteolytic enzymes, belonging to the matrix metalloproteinase family, have been characterized as key players in the intricate network between inflammatory signals and changes in vascular endothelium and dermal ECM.29,30 The imbalance between MMPs and their inhibitors TIMPs is able to impair wound healing via deleterious degradation process of ECM, leading to loss of epidermal integrity characteristic of chronic hard-to-heal wounds.32 Noteworthy, some MMPs are related to healing conditions in ulcers characterized by granulation tissue, whereas other MMPs are mainly found in inflammatory hard-to-heal wound with chronic condition of inflammation.30 The list of proteolytic enzymes in wound microenvironment is reported in Table 2. Recently, it has been demonstrated that in wound fluids collected from chronic venous leg ulcers, pro- and anti-inflammatory cytokines as well as growth factors expressed in the wound microenvironment may represent useful markers for demonstrating that cytokine dysregulation guide deleterious inflammatory processes of ECM, and identifying chronic hard-to-heal wounds.32 Moreover, these biomarkers may represent possible targets for a better therapeutic approach. Noteworthy, some cytokines and growth factors are related to healing conditions in ulcers characterized by granulation tissue, suggesting the optimal therapeutic conditions for improving the healing of CVI ulcers.33

The identification of accurate biomarkers in wound microenvironments, the explanation of CVD disease mechanisms, the stratification of patients groups according to healing process, and the development of protocols and assay platforms for using clinical biomarkers as diagnostic indicators of healing status may represent a crucial subject for future directions in CVD studies.

This overview highlights the news in venous wound research, suggesting the characterization of known wound biomarkers, the identification of new biomarkers and the future development of new panels of biomarkers for the prediction of chronic wound outcome, in conjunction to possible effective therapeutic potential.

Finally, in order to assess the potential usefulness of the clinical biomarkers in the field of CVI in a way that can be useful for clinicians, we highlight and may suggest that currently genomic biomarkers can only give information (of low to medium risk) of developing clinical conditions related to CVI and CVD, due to multigenic participation in the disease.34

For what concerns the proteomic biomarkers (including cytokinome and degradome), the increasing number of studies put the research approach at a good point of developing and are coming to be used in the clinical practice for disease predisposition, identification of healing status and follow-up tracking during pharmacologic treatment.

In the near future the hope is to validate stratification risk, which may integrate data from molecular and biochemical biomarkers in conjunctions to clinical assessment to provide information on CVI early diagnosis, staging and therapeutic efficacy.

Table 2. Inflammatory and proteolytic biomarkers in chronic wound fluids from inflammatory and granulating venous leg ulcers.

<table>
<thead>
<tr>
<th>Inflammatory</th>
<th>Granulating</th>
</tr>
</thead>
<tbody>
<tr>
<td>↑ IL-1β</td>
<td>↑ IP-10</td>
</tr>
<tr>
<td>↑ IL-12</td>
<td>↑ RANTES</td>
</tr>
<tr>
<td>↑ IL-10</td>
<td>↑ PDGF-BB</td>
</tr>
<tr>
<td>↑ IL-8/CXCL8</td>
<td>↑ MMP-1</td>
</tr>
<tr>
<td>↑ GM-CSF</td>
<td>↑ MMP-2</td>
</tr>
<tr>
<td>↑ VEGF</td>
<td>↑ MMP-9</td>
</tr>
<tr>
<td>↑ MMP-2</td>
<td>↑ MMP-13</td>
</tr>
<tr>
<td>↑ MMP-12</td>
<td>↑ TIMP-4</td>
</tr>
<tr>
<td>↑ TIMP-1</td>
<td>↑ TIMP-2</td>
</tr>
</tbody>
</table>

Table 3. Contraindications to compression therapy.

<table>
<thead>
<tr>
<th>Absolute contraindications</th>
<th>No ref.</th>
<th>Relative contraindications</th>
<th>No ref.</th>
<th>Contraindications without classification</th>
<th>No ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arterial occlusive disease</td>
<td>35,42,43</td>
<td>Diabetes mellitus; peripheral neuropathy</td>
<td>47,48</td>
<td>Heart failure</td>
<td>Heart failure</td>
</tr>
<tr>
<td>Heart failure</td>
<td>35,42,43</td>
<td>Heart failure</td>
<td>35,42,43</td>
<td>Neuropathy</td>
<td>39</td>
</tr>
<tr>
<td>Ankle brachial pressure index &lt;0.5-0.8</td>
<td>35,42,43,44</td>
<td>Compensated peripheral arterial occlusive disease</td>
<td>42,43,45</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Extensive thromboembolitis, thrombosis or suspected thrombosis</td>
<td>45,46</td>
<td>Intolerance to dressing material/allergies</td>
<td>42,43,45</td>
<td>Extensive thromboembolitis, thrombosis or suspected thrombosis</td>
<td>39</td>
</tr>
<tr>
<td>Phlegmasia coerulea dolens</td>
<td>45</td>
<td>Skin diseases</td>
<td>43,46</td>
<td>Erysipelas</td>
<td>39</td>
</tr>
<tr>
<td>Erysipelas</td>
<td>35,43,44</td>
<td>Malignant diseases</td>
<td>43,47</td>
<td>Serious non-controlled hypertension</td>
<td>42,46</td>
</tr>
<tr>
<td>Serious non-controlled hypertension</td>
<td>35,43,44</td>
<td>Ankle brachial pressure index &lt;0.5-0.8</td>
<td>35,42</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Contraindications, risk factors, adverse events in venous leg ulcer compression therapy

Currently, there is a lack of clarity on contraindications, risk factors, adverse events and complications when applying compression therapy for venous leg ulcer patients.35

A literature review was conducted of current guidelines on venous leg ulcer prevention, management and maintenance (Table 35-48).

The development of guidelines was done by various disciplines and organizations, including phlebologists, dermatologists, specialized nurses, vascular surgeons and multidisciplinary groups.

Many of the selected guidelines used literature that was more than 10 years old.36 As this is a field that is evolving and new technologies are making their way to the market, this may pose issues.36

Guidelines agreed on the following absolute contraindications: arterial occlusive disease, heart failure and ankle brachial pressure index (ABPI) <0.5, but gave conflicting recommendations on relative contraindications (caution should be used when procedures are used).

Arterial circulation in the lower limbs and clinical implications of ABPI may be defined38-42 as follows: normal ABPI >1.00-1.3, compression therapy can be applied. For those with an ABPI between 0.8-1.0 the presence of mild peripheral disease should be considered and compression can be applied with caution. Significant arterial disease may be present in case of an ABPI ≤0.8-0.6 and only modified compression can be used with caution. Referral to a vascular specialist is recommended in these cases.

Critical ischemia is likely to be present in those with an ABPI of <0.5, compression is contraindicated and urgent referral to a vascular specialist is needed.

Some guidelines report contraindications without classification in absolute and relative.37,38 Extensive thrombophlebitis, thrombosis or suspected thrombosis were recognized as contraindications or absolute contraindications,30,31 but the majority of guidelines recommend for patients with proximal deep vein thrombosis to wear graduated compression stockings.40

Moreover definitions were unclear and not consistent. As practice in various countries may differ greatly from some of the countries where guidelines were developed, recommendations given may not be achievable. Often guidelines are text heavy and not designed for practical clinical use. Patient focused clinical pathways may be a more practical way forward to optimize care for venous leg ulcer patient management.41

Pressure marks, necrosis, friction damage and leg ulcer formation, as a result of poorly applied compression or the wrong type of compression, were identified as risk factors and adverse events in all of the selected guidelines.35-48

Complications of compression therapy can almost always be prevented when adequate assessment is performed and clinicians are skilled in applying compression. Effective patient education improves patient’s outcome.41

Venous ulcers and drugs: an adjuvant therapy?

In recent years, an increasing number of drugs was widely used in the treatment of the chronic venous disease. Their role in venous ulcers healing remains controversial.

Pentoxifylline was the first drug to be extensively studied: the rationale for its use is based on its anti-inflammatory and hemorheological properties consisting in reducing blood viscosity, decreasing platelet aggregation, antiradical action and reducing cytokine expression.49 A Cochrane systematic review of 7 randomized controlled trials (RCTs), involving 659 patients, showed pentoxifylline with compression to be more effective than placebo and compression in term of complete ulcer healing over 8 to 24 weeks (64% of healing vs 40%).50

Micronized purified flavonoid fraction (MPFF) has shown to accelerate venous ulcer healing. Of particular interest is its action on inflammatory reactions associated with venous hypertension. MPFF modifies leukocyte-endothelial interactions, inhibiting the expression of intercellular adhesion molecule and vascular adhesion molecule, as well as the expression of leukocyte adhesion molecule on monocytes and neutrophils.51,52 In a meta-analysis of five prospective RCTs involving 723 patients with venous ulcers MPFF therapy was compared with compression therapy, alone in three studies, combined with placebo in two studies. Ulcers between 5 and 10 cm² had a 40% better chance of healing with MPFF, whereas in venous ulcers aged between 6- and 12-months flavonoids increase ulcer healing by 44%.53

Another group of drugs tested in co-adjuvant ulcer therapy comprises the glycosaminoglycans (GAGs).

Sulodexide, a sulfated polysaccharide complex extracted from porcine intestinal mucosa, has an antithrombotic action, restores integrity and permeability of endothelial cells, modulates inflammatory pathways in chronic venous disease.34,35 Four RCTs, involving 488 patients, demonstrated that oral sulodexide plus compression, compared with compression alone, is more effective at increasing healing rates at 1 to 3 months.56

Mesoglycan, composed of highly purified natural GAGs, acts through an enhancement in endogenous fibrinolysis and in antithrombotic properties of plasma. A multi-center double-blind placebo-controlled RCT, involving 183 patients, at 24 weeks showed healing of venous ulcers in 97% of the mesoglycan group and in 82% of the placebo group.

Methodological shortcomings and bias limit the validity of results from trials involving other drugs.

Trials to determine whether low-dose aspirin therapy may improve time to healing and decrease the number of recurrent venous ulcers are in progress.77

If we analyze papers on pharmacological treatment of venous leg ulcers, published in 2016, we can find statements which support the use of pentoxifylline in term of effectiveness and promising evidence.58,59

In an open-label, observational, non-parallel trial on 70 patients, the use of sulodexide and diosmin-hesperidin was effective in accelerating ulcer healing, controlling pain and improving lipodermatosclerosis.60 A Cochrane review, including four trials with a total of 463 participants, showed that sulodexide may increase the healing of venous ulcers, but the evidence is only of low quality.61

Vasoactive drugs were proven to be effective in treating symptoms and slow down the progression of chronic venous disease. In venous ulcers management, there are no high-quality clinical trials on phlebotomous drugs which consider pain, quality of life and healing rate as parameters.62,63

Pending questions remain. We don’t know if the dose of a drug should be the same for varicose veins and for venous ulcers and if a drug has the same efficacy in different hemodynamic patterns. Moreover, there are no recommended limits on the duration of treatment and there is no information on the recurrence rates.

It emerges the need to study serum inflammatory markers to know more about targets of venotonics therapy and to consider pain and quality of life as critical parameters of efficacy. Finally, cost-effectiveness relationship should guide our choices.
Conclusions

Venous leg ulcers are characterized by a long healing process and repeated cycles of ulceration. Multiple studies were conducted to identify risk factors for delayed healing and recurrence of venous leg ulcers. Moreover, many studies were published to determine whether particular dressings or topical agents improve the probability of healing of venous leg ulcers in any care setting and to rank treatments in order of effectiveness, with assessment of uncertainty and evidence quality.

Our work aims to draw attention on open issues and controversies regarding venous ulcers management.

We do not propose strict rules, but we offer suggestions and encourage study and research.

There are very few epidemiological studies to generate data from. Point prevalence (from 0.08% up to 0.6%) and overall or lifetime prevalence (in the range of 1-2%) values are likely to stay high or increase without surgical intervention because there are no data showing that conservative management can reduce them. Although the number of factors involved in the etiology of chronic wounds is extremely high, a recognition of functional gene variants significantly involved in wound healing and venous ulcer establishment, may help our prognosis, diagnosis and treatment capabilities of chronic wounds. Moreover, the characterization of known wound biomarkers, the identification of new biomarkers and the future development of new panels of biomarkers put the research approach at a good point for the prediction of chronic wound outcome, in conjunction to possible effective therapeutic potential.

In the same way, it is of great importance to identify and follow diagnostic-therapeutic protocols that provide for proper use of compression therapy and surgery. Currently there is a lack of clarity on contraindications, risk factors, adverse events and complications, when applying compression therapy for venous leg ulcer patients. Often guidelines are text heavy and not designed for practical clinical use. Patient focused clinical pathways may be a more practical way forward to optimize care for venous leg ulcer patient management.

Pharmacological therapy has shown that it can accelerate healing times and studies support the use of pentoxifylline, micronized purified flavonoid fraction and sulodexide. Some open questions remain about the duration of treatment and recurrence rates after pharmacological treatment.

References

25. Raffetto JD. Dermal pathology, cellular biology, and inflammation in chronic


